A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts). (October 2020) - Lee, V.; Zahurak, M.; Cercek, A.; Verheul, H.; Lenz, H.; Jones, P.; Baylin, S.; Parkinson, R.; Rami, V.; Lilly, E.; Miles, T.; Brown, T.; et al.